Product logins

Find logins to all Clarivate products below.


Pulmonary Hypertension | Disease Landscape and Forecast | G7 | 2016

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for PH agents. Commercial interest in PH has increased as a result of recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease. 

Related Market Assessment Reports

Report
Hypertension – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of hypertension includes epidemiological estimates for key patient populations across 45 countries worldwide. We report the prevalence of hypertension for each…
Report
Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (G7)
Pulmonary hypertension (PH) is a devastating disease characterized by high blood pressure that affects the pulmonary arteries and the right side of the heart leading to substantial morbidity and…
Report
Pulmonary Hypertension | Disease Landscape & Forecast | G7 | 2025
Pulmonary hypertension (PH) is a devastating disease characterized by high blood pressure that affects the pulmonary arteries and the right side of the heart leading to substantial morbidity and…
Report
Pulmonary Arterial Hypertension | Treatment Algorithms: Claims Data Analysis | US | 2025
Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder characterized by high blood pressure in the arteries of the lungs. The progressive condition is associated with…
Report
Pulmonary Hypertension | Disease Landscape & Forecast | G7 | 2024
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of PH, the potential commercial opportunities for drugs approved for…